1247 related articles for article (PubMed ID: 17592153)
1. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
Du Y; Cullum I; Illidge TM; Ell PJ
J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
3. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18.
Basu D; Siegel BA; McDonald DJ; Nussenbaum B
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):801-5. PubMed ID: 17709620
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
5. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
6. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
7. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.
Liu FY; Yen TC; Chen MY; Lai CH; Chang TC; Chou HH; Hong JH; Chen YR; Ng KK
Cancer; 2009 Dec; 115(23):5470-80. PubMed ID: 19739235
[TBL] [Abstract][Full Text] [Related]
8. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
9. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography.
Bar-Shalom R; Kagna O; Israel O; Guralnik L
Cancer; 2008 Dec; 113(11):3213-21. PubMed ID: 18924145
[TBL] [Abstract][Full Text] [Related]
11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
12. [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
Xing Y; Zhao JH; Wang TS; Qiao WL; Che WJ
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):129-33. PubMed ID: 19538891
[TBL] [Abstract][Full Text] [Related]
13. F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas.
Iagaru A; Quon A; McDougall IR; Gambhir SS
Clin Nucl Med; 2006 Dec; 31(12):754-60. PubMed ID: 17117068
[TBL] [Abstract][Full Text] [Related]
14. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment.
Jerushalmi J; Frenkel A; Bar-Shalom R; Khoury J; Israel O
J Nucl Med; 2009 Jun; 50(6):849-53. PubMed ID: 19443604
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas.
Iagaru A; Chawla S; Menendez L; Conti PS
Nucl Med Commun; 2006 Oct; 27(10):795-802. PubMed ID: 16969262
[TBL] [Abstract][Full Text] [Related]
16. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
17. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance.
Israel O; Yefremov N; Bar-Shalom R; Kagana O; Frenkel A; Keidar Z; Fischer D
J Nucl Med; 2005 May; 46(5):758-62. PubMed ID: 15872347
[TBL] [Abstract][Full Text] [Related]
18. Prevention of brown adipose tissue activation in 18F-FDG PET/CT of breast cancer patients receiving neoadjuvant systemic therapy.
Aukema TS; Vogel WV; Hoefnagel CA; Valdés Olmos RA
J Nucl Med Technol; 2010 Mar; 38(1):24-7. PubMed ID: 20159933
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
20. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
Groheux D; Moretti JL; Baillet G; Espie M; Giacchetti S; Hindie E; Hennequin C; Vilcoq JR; Cuvier C; Toubert ME; Filmont JE; Sarandi F; Misset JL
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):695-704. PubMed ID: 18436392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]